FLT3 and acute myeloid leukemia: The results showed that combination treatment significantly prolonged the survival time of the FLT3-ITD AML xenograft model mice (hazard ratios for death and 95% confidence intervals: combination vs gilteritinib, 0.466-4.132 and 0.242 - 2.142; combination vs mitoxantrone-liposome, 0.5698 - 6.649 and 0.1504 - 1.755; combination vs DMSO, 0.9884 - 9.813 and 0.1019 - 1.012) (Fig. 11e).